WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will showcase its latest developments in immuno-inflammatory research at three prominent healthcare investment conferences in November, reflecting growing investor interest in the company’s clinical-stage pipeline.
Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ leadership team are slated to participate in fireside chats across multiple global events. On November 12, Dr. Walker will appear at 11:00 a.m. EST during the Guggenheim 2nd Annual Healthcare Conference in Boston. Later that day, at 1:20 p.m. EST, President and Chief Operating Officer Dr. Hugh Davis will join discussions at the Stifel 2025 Healthcare Conference in New York.
A week later, on November 17 at 2:00 p.m. GMT (9:00 a.m. EST), Dr. Walker will speak at the Jefferies Global Healthcare Conference in London, underscoring Aclaris’ international engagement with the medical and investment communities.
Live and archived webcasts of each event will be available for at least 30 days on the company’s website at www.aclaristx.com.
Aclaris Therapeutics is advancing a multi-stage pipeline focused on novel therapies for patients suffering from immuno-inflammatory conditions with limited treatment options. The Pennsylvania-based biopharmaceutical company continues to leverage its research and development platform to drive innovation in precision medicine and address unmet needs in autoimmune and inflammatory disease care.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.